Last $81.29 USD
Change Today +0.86 / 1.07%
Volume 2.1M
EW On Other Exchanges
New York
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/13 - $86.11
52 Week Low
12/13/13 - $60.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

edwards lifesciences corp (EW) Related Businessweek News

No Related Businessweek News Found

edwards lifesciences corp (EW) Details

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers surgical heart valve therapy products, such as tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve; and produces pericardial valves from biologically inert animal tissue. Its surgical heart valve therapy products include Carpentier-Edwards PERIMOUNT pericardial valve that comprise PERIMOUNT Magna Ease valves for aortic and mitral replacement; ThruPort systems that enable minimal incision valve surgery; and protection cannulae that is used during cardiac surgery in venous drainage, aortic perfusion, venting, and cardioplegia delivery. The company also provides transcatheter heart valves portfolio that includes technologies designed to treat heart valve disease using catheter-based approaches, as well as critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; Swan-Ganz line of pulmonary artery and PreSep continuous venous oximetry catheters for measuring central venous oxygen saturation; VolumeView sensor-catheters; FloTrac continuous cardiac output monitoring system, a minimally invasive cardiac monitoring technology for fluid optimization; and EV1000 clinical monitoring platform, which displays a patient's physiologic status. Its critical care products also include disposable pressure monitoring devices and closed blood sampling systems to help protect patients and clinicians from the risk of infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as balloon-tipped, catheter-based embolectomy products, surgical clips, and clamps. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

8,600 Employees
Last Reported Date: 02/28/14
Founded in 1999

edwards lifesciences corp (EW) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $879.8K
Corporate Vice President of Europe, Middle Ea...
Total Annual Compensation: $607.8K
Corporate Vice President of Critical Care & V...
Total Annual Compensation: $472.4K
Corporate Vice President of Heart Valve Thera...
Total Annual Compensation: $440.6K
Compensation as of Fiscal Year 2013.

edwards lifesciences corp (EW) Key Developments

Edwards Lifesciences Corporation Receives CE Mark for the Advanced EDWARDS INTUITY Elite Valve System

Edwards Lifesciences Corporation announced it has received CE Mark for the advanced EDWARDS INTUITY Elite valve system. This next-generation, rapid deployment system facilitates smaller incisions in surgical aortic valve replacement (AVR) procedures, and is built upon extensive evidence supporting the durability of the Carpentier-Edwards PERIMOUNT heart valve design. The next-generation EDWARDS INTUITY Elite valve system combines a unique balloon-expandable frame with Edwards' proven pericardial PERIMOUNT platform, which has demonstrated durability up to 25 years in published studies. The new system has design improvements intended to improve ease of use, including a flexible and lower profile delivery system that is designed to facilitate access and visibility through smaller incisions.

Edwards Lifesciences Announces First Human Implants with Mitral Transcatheter Valve System

Edwards Lifesciences Corp. announced the successful completion of the first three human implants of its FORTIS mitral transcatheter heart valve, which were performed in February and March by the Heart Team at St. Thomas' Hospital in London. The FORTIS transcatheter mitral valve features Edwards' most advanced, treated bovine pericardial tissue. It features a cloth-covered self-expanding frame designed to minimize paravalvular leak, and a unique anatomical anchoring system. This series of implants is being performed via a transapical approach to allow direct surgical access to the mitral valve complex.

Edwards Lifesciences Approves Amendment to Bylaws

On February 20, 2014, the Board of Edwards Lifesciences Corp. amended and restated the Company's Bylaws (the Bylaws). In addition to certain technical, conforming, and clarifying changes, these amendments include the following additional changes: Special Meetings of Stockholders. Section 6 of Article I of the Bylaws was amended to provide that holders of 25% of the outstanding shares of the Company's common stock have the right to call a special meeting of stockholders. Section 6 was also amended to set forth the related ownership, procedural, and disclosure requirements such stockholder(s) must satisfy in order to call a special meeting of stockholders. Election of Directors. Section 2(b) of Article I of the Bylaws was amended to clarify that the determination of whether an election of directors is contested for purposes of applying the majority vote standard will be made ten days before the proxy statement is mailed to stockholders. Advance Notice of Director Nominations and New Business Proposals. Various sections of Article I of the Bylaws were amended to clarify that the adjournment or postponement of an annual or special meeting of stockholders will not alter or extend the time period within which a stockholder must provide notice for director nominations or new business proposals to be considered at such meeting. Section 2(e) of Article I was also amended to specify the deadline for additional director nominations if the number of directors to be elected to the Board is increased effective after the deadline for advance notice of director nominations. In addition, Section 9(d) of Article I was amended to require enhanced disclosures in connection with stockholder proposals of new business for consideration at any annual or special meeting of stockholders. Various sections of Article I were also amended to provide that if a stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders, as applicable, to present a director nomination or proposed item of new business, such nomination shall be disregarded or such proposed business shall not be transacted. The amendments also clarify who will be considered a qualified representative' of the stockholder for this purpose. Special Meetings of the Board of Directors. Article III and Section 4 of Article II of the Bylaws were amended to provide that directors seeking to waive notice of any special meeting of the Board or any committee of the Board may do so by electronic transmission. Conduct of Stockholder Meetings. Section 8 of Article I of the Bylaws was amended to clarify the responsibility and authority of the chairman of any annual or special meeting of stockholders to conduct such meeting. Exclusive Forum for Certain Litigation. Section 5 of Article VIII of the Bylaws was added to designate, subject to certain exceptions, the Court of Chancery of the State of Delaware as the sole and exclusive forum for the adjudication of certain derivative and other lawsuits against the Company, its directors, officers, or employees.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $81.29 USD +0.86

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $57.26 USD -0.44
MEDNAX Inc $60.45 USD +0.01
Mettler-Toledo International Inc $233.50 USD +4.65
ResMed Inc $47.44 USD +0.95
Varian Medical Systems Inc $80.28 USD -0.61
View Industry Companies

Industry Analysis


Industry Average

Valuation EW Industry Range
Price/Earnings 23.4x
Price/Sales 4.3x
Price/Book 5.6x
Price/Cash Flow 21.6x
TEV/Sales 3.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at